Evidence map›Paper›PMID 32824256›Full record

ArticlePolymers2020

Nanoformulation Design Including MamC-Mediated Biomimetic Nanoparticles Allows the Simultaneous Application of Targeted Drug Delivery and Magnetic Hyperthermia.

Ylenia Jabalera, Francesca Oltolina, Ana Peigneux, Alberto Sola-Leyva, Maria P Carrasco-Jiménez, Maria Prat, Concepcion Jimenez-Lopez, Guillermo R Iglesias

Abstract read
In one paragraph

Article in Polymers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ylenia JabaleraDepartment of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.ORCID 0000-0003-1786-959X
Francesca OltolinaDepartment of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.
Ana PeigneuxDepartment of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.
Alberto Sola-LeyvaDepartment of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain.ORCID 0000-0003-1388-1532
Maria P Carrasco-JiménezDepartment of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain.ORCID 0000-0003-1300-5196
Maria PratDipartimento di Scienze della Salute, Università del Piemonte Orientale "A. Avogadro", Via Solaroli 17, 28100 Novara, Italy.ORCID 0000-0003-0262-9729
Concepcion Jimenez-LopezDepartment of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-5645-2079
Guillermo R IglesiasDepartment of Applied Physics, Faculty of Sciences, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-5623-1516

Funding

ALTERNATIVE PATHWAYS OF T CELL ACTIVATIONK08AR002017 · NIAMS · VANDERBILT UNIVERSITY · PI BYRD, VICTOR M · 1998 to 2002
$348k
Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía CGL2016-7672Marie Skłodowska-Curie grant 754446Ministerio de Economía, Industria y Competitividad, Gobierno de España RYC-2014-6901Ministerio de Educación, Ciencia y Deporte y Competitividad FPU16_04580Progetto di Ricerca Fondi di Ateneo per la Ricerca - FAR 2017 Progetto di Ricerca Fondi di Ateneo per la Ricerca - FAR 2017Programa Operativo FEDER 2014-2020 A1-FQM-341-UGR18, C-FQM-497-UGR18Programa Operativo FEDER 2014-2020 A-BIO-376-UGR18
6 · The paper itself

Abstract

The design of novel nanomaterials that can be used as multifunctional platforms allowing the combination of therapies is gaining increased interest. Moreover, if this nanomaterial is intended for a targeted drug delivery, the use of several guidance methods to increase guidance efficiency is also crucial. Magnetic nanoparticles (MNPs) allow this combination of therapies and guidance strategies. In fact, MNPs can be used simultaneously as drug nanocarriers and magnetic hyperthermia agents and, moreover, they can be guided toward the target by an external magnetic field and by their functionalization with a specific probe. However, it is difficult to find a system based on MNPs that exhibits optimal conditions as a drug nanocarrier and as a magnetic hyperthermia agent. In this work, a novel nanoformulation is proposed to be used as a multifunctional platform that also allows dual complementary guidance. This nanoformulation is based on mixtures of inorganic magnetic nanoparticles (M) that have been shown to be optimal hyperthermia agents, and biomimetic magnetic nanoparticles (BM), that have been shown to be highly efficient drug nanocarriers. The presence of the magnetosome protein MamC at the surface of BM confers novel surface properties that allow for the efficient and stable functionalization of these nanoparticles without the need of further coating, with the release of the relevant molecule being pH-dependent, improved by magnetic hyperthermia. The BM are functionalized with Doxorubicin (DOXO) as a model drug and with an antibody that allows for dual guidance based on a magnetic field and on an antibody. The present study represents a proof of concept to optimize the nanoformulation composition in order to provide the best performance in terms of the magnetic hyperthermia agent and drug nanocarrier.

Indexed as

biomimetic magnetic nanoparticlesdoxorubicinmagnetic hyperthermiamagnetic nanoparticlesMamCtumor combined dual targeting

Identifiers

PMID32824256
PMCPMC7465699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.